Skip to content
Search

Latest Stories

Antisemitic comment: GPhC ordered to reconsider FtP decision on London pharmacist

The High Court today (23 June) quashed a decision by the General Pharmaceutical Council (GPhC) in relation to the alleged antisemitic comments made by London pharmacist Nazim Ali.

In an appeal filed by the Professional Standards Authority (PSA), the court found that the Fitness to Practice (FtP) committee of the GPhC erred in taking into account of the intention and character of Ali when the allegation was, however, simply that the words used by him were offensive and antisemitic.


“[The FtP committee] wrongly took account of Mr Ali’s intention when assessing whether his language was objectively antisemitic. It wrongly took account of his character when assessing whether his language was objectively antisemitic. And it erroneously failed to assess whether the remarks, considered cumulatively, were objectively antisemitic, as opposed to whether each remark in isolation was anti-Semitic,” Justice Johnson, of the Queen's Bench division of the court, said in the judgment.

The case pertains to a rally led by Ali on 18 June 2017 to demonstrate support for Palestinian rights, in which he made the comments in question. Currently the managing partner of Chelsea Pharmacy in London, he was not acting as a pharmacist when the rally took place.

After an allegation was made against him that he had thereby said things that were antisemitic and offensive, FtP committee in November 2020 ruled that his comments were offensive but not antisemitic. The committee concluded that Ali’s use of the words, which he admitted were grossly offensive, amounted to serious misconduct and that his fitness to practise was thereby impaired, and issued him with a warning.

The PSA appealed to the High Court against the finding, saying the committee had erred in its approach and incorrectly taken into account his intention and character, rather than taking a purely objective approach.

The GPhC did not contest the appeal, agreeing to the contention by the PSA.

“We will make sure the learnings from this case and the High Court judgment are shared across the organisation and our committees,” Duncan Rudkin, chief executive of the GPHC, said, adding that the further FtP hearing for Ali will be scheduled at the earliest opportunity.

Contesting the appeal, Ali, who also performs as a stand-up comedian, noted that a warning would be appropriate even if his language is found to be antisemitic as that was the sanction suggested by the GPhC in its opening submissions at FtP hearing.

Justice Johnson said he is “in principle, sympathetic to the suggestion”, but noted that the case does engage “significant questions of public confidence.”

“It is vitally important that all sections of the community are able to place trust and confidence in pharmacists,” he wrote in the judgment. “That is vividly illustrated by the current pandemic, and the need that all communities are able to have confidence in advice given by pharmacists and other professionals about the risks and benefits of vaccination. Public confidence is an important consideration when considering sanction.”

The judge decided to remit the case to the FtP committee for reconsideration, saying that the committee is better placed to make an assessment as to the appropriate sanction to be imposed.

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
​The next generation of BD Rowa Smart launched

The latest BD Rowa™ Smart introduces a more intuitive user interface.

Photo credit: BD Rowa

BD Rowa unveils next-generation smart dispensing robot with sustainable design

Leading medical technology company BD Rowa has announced the launch of the next generation of its smart dispensing robot, offering enhanced convenience with a sustainable design.

Currently in its final development phase, the latest BD Rowa™ Smart introduces a more intuitive user interface designed to streamline operations and enhance the user experience.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less